Premium
Chemo‐endocrine therapy in patients with stage D2 prostate cancer
Author(s) -
Kubota Yoko,
Nakada Teruhiro,
Imai Kyoichi,
Yamanaka Hidetoshi,
Sakai Hideki,
Saito Yutaka,
Tomaru Yukio,
Kitamura Koichi,
Sugano Osamu,
Sasagawa Isoji
Publication year - 1995
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.2990260110
Subject(s) - medicine , prostate cancer , endocrine system , stage (stratigraphy) , prostate , oncology , cancer , prostate disease , gynecology , hormone , biology , paleontology
There have only been a few studies of chemo‐endocrine therapy compared with endocrine therapy alone in newly diagnosed prostate cancer patients. We assessed the effects of these two therapies by comparing long‐term survival rates. One hundred and twenty‐nine patients were entered in this study between November 1977 and March 1992. Seventy‐seven patients were treated with endocrine therapy alone. Other 52 patients received chemo‐endocrine therapy, which included orchiectomy and/or diethylstilbestrol diphosphate (DES‐DP) plus Cisplatin, with or without other cytotoxic agents. All patients had bone metastasis at the beginning of the study. There was a significant difference in survival between patients who received endocrine therapy and chemo‐endocrine therapy ( P = 0.0078). That is, survival rate was superior for the chemoendocrine therapy patients throughout the entire follow‐up period. These data suggest that early chemo‐endocrine therapy containing Cisplatin, with or without maintenance chemotherapy, is a potentially effective treatment for newly diagnosed metastatic prostate cancer and is worth further investigation via a randomized trial.